speb/financial-data huggingface dataset:
4429.T — Peter Lynch category analysis (annual, as of 2022-02-28)
Sector: Technology | Industry: Software - Application
Lynch category: Slow Grower (confidence: Low)
Market cap (USD): 62724657.15521716
Net income (USD): 2828638.172694238
P/E ratio: 22.174860595716567
P/B ratio: 3.214677896161391
Pays dividend: no
Net asset value (USD): 19423732.479667764
Net cash (USD): 12215547.672607718
Net cash to market cap %: 19.474873561093162
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 9.985034162335658 (Safe Zone)
Piotroski F-score: 2 (Weak)
4429.T — Peter Lynch category analysis (annual, as of 2023-02-28)
Sector: Technology | Industry: Software - Application
Lynch category: Slow Grower (confidence: Low)
Market cap (USD): 53544728.19835681
Net income (USD): 3109463.028169014
EPS growth %: 9.92791719300367
Revenue growth %: 10.666996166346374
Smoothed growth %: 9.92791719300367
P/E ratio: 17.21992759305656
P/B ratio: 2.949965383900353
PEG ratio: 1.734495489667426
Pays dividend: no
Net asset value (USD): 17963020.833333336
Net cash (USD): 7142356.220657278
Net cash to market cap %: 13.339046552255098
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 4.840633043964062 (Safe Zone)
Piotroski F-score: 4 (Weak)
4429.T — Peter Lynch category analysis (annual, as of 2024-02-29)
Sector: Technology | Industry: Software - Application
Lynch category: Slow Grower (confidence: Low)
Market cap (USD): 46387283.30014603
Net income (USD): 1785616.6202044338
EPS growth %: -42.57475956368319
Revenue growth %: 20.54110959715969
EPS 2-year CAGR %: -20.547894455390548
Smoothed growth %: -42.57475956368319
P/E ratio: 25.978299471045013
P/B ratio: 2.5249481737167536
Pays dividend: no
Net asset value (USD): 18120496.482145227
Net cash (USD): -265551.57307845727
Net cash to market cap %: -0.5724663187542637
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 3.913197602983365 (Safe Zone)
Piotroski F-score: 4 (Weak)
4429.T — Peter Lynch category analysis (annual, as of 2025-02-28)
Sector: Technology | Industry: Software - Application
Lynch category: Fast Grower (confidence: Medium)
Market cap (USD): 25529058.28944737
Net income (USD): 2369962.002533165
EPS growth %: 32.72513123572012
Revenue growth %: 21.24511554825345
EPS 2-year CAGR %: -12.69723616544015
Smoothed growth %: 32.72513123572012
P/E ratio: 10.771927255441355
P/B ratio: 1.2643096087970482
Pays dividend: no
Net asset value (USD): 19887194.1870542
Net cash (USD): -2348223.451769881
Net cash to market cap %: -9.198237651956543
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 3.1829797561184545 (Safe Zone)
Piotroski F-score: 6 (Neutral)
4429.T — Peter Lynch category analysis (annual, as of 2026-02-28)
Sector: Technology | Industry: Software - Application
Lynch category: Slow Grower (confidence: Low)
Market cap (USD): 27429278.19838316
Net income (USD): 1692461.18311305
EPS growth %: -28.586990791243032
Revenue growth %: 15.921235972200028
EPS 2-year CAGR %: -2.643433610413537
Smoothed growth %: -28.586990791243032
P/E ratio: 16.206739907576946
P/B ratio: 1.2890766445565196
Pays dividend: no
Net asset value (USD): 21014198.63980495
Net cash (USD): -15249435.390735272
Net cash to market cap %: -55.59546729754691
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 2.4098214410293624 (Grey Zone)
Piotroski F-score: 4 (Weak)
4434.T — Peter Lynch category analysis (quarterly, as of 2025-05-31)
Sector: Technology | Industry: Software - Infrastructure
Lynch category:  (confidence: Low)
Market cap (USD): 126789740.47948255
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 0 (Weak)
4434.T — Peter Lynch category analysis (quarterly, as of 2026-02-28)
Sector: Technology | Industry: Software - Infrastructure
Lynch category:  (confidence: Low)
Market cap (USD): 98106985.93609649
P/B ratio: 1.5706869593460928
Pays dividend: no
Net asset value (USD): 61117368.150904655
Net cash (USD): -24818754.010008983
Net cash to market cap %: -25.29764192957173
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4434.T — Peter Lynch category analysis (quarterly, as of 2026-05-31)
Sector: Technology | Industry: Software - Infrastructure
Lynch category:  (confidence: High)
Market cap (USD): 87951634.53255478
Dividend yield: 0.02
Pays dividend: yes
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4478.T — Peter Lynch category analysis (quarterly, as of 2024-09-30)
Sector: Technology | Industry: Software - Application
Lynch category:  (confidence: Low)
Market cap (USD): 1014600102.507354
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 0 (Weak)
4478.T — Peter Lynch category analysis (quarterly, as of 2024-12-31)
Sector: Technology | Industry: Software - Application
Lynch category:  (confidence: Low)
Market cap (USD): 1139515309.5268257
P/B ratio: 9.727684046088662
Pays dividend: no
Net asset value (USD): 101849544.55697815
Net cash (USD): 28000668.83240968
Net cash to market cap %: 2.4572437595451637
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4478.T — Peter Lynch category analysis (quarterly, as of 2025-06-30)
Sector: Technology | Industry: Software - Application
Lynch category:  (confidence: Low)
Market cap (USD): 1576991923.6437862
P/B ratio: 11.590480388547569
Pays dividend: no
Net asset value (USD): 107576944.36756158
Net cash (USD): 26399100.47052312
Net cash to market cap %: 1.674016212430914
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4478.T — Peter Lynch category analysis (quarterly, as of 2025-09-30)
Sector: Technology | Industry: Software - Application
Lynch category:  (confidence: Low)
Market cap (USD): 1402063223.654105
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4478.T — Peter Lynch category analysis (quarterly, as of 2025-12-31)
Sector: Technology | Industry: Software - Application
Lynch category:  (confidence: Low)
Market cap (USD): 911405435.4580909
P/E ratio: 1.3129915334548279
P/B ratio: 8.860911574402866
Pays dividend: no
Net asset value (USD): 92474189.62981907
Net cash (USD): -5896707.371651441
Net cash to market cap %: -0.6469905864328794
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4480.T — Peter Lynch category analysis (quarterly, as of 2025-03-31)
Sector: Healthcare | Industry: Health Information Services
Lynch category:  (confidence: Low)
Market cap (USD): 608468755.3802967
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 0 (Weak)
4480.T — Peter Lynch category analysis (quarterly, as of 2025-06-30)
Sector: Healthcare | Industry: Health Information Services
Lynch category:  (confidence: Low)
Market cap (USD): 661126356.7672294
P/B ratio: 5.2893036470327734
Pays dividend: no
Net asset value (USD): -42679213.94962635
Net cash (USD): -109562690.28508164
Net cash to market cap %: -16.572125610120953
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4480.T — Peter Lynch category analysis (quarterly, as of 2025-12-31)
Sector: Healthcare | Industry: Health Information Services
Lynch category:  (confidence: Low)
Market cap (USD): 370555281.3247235
P/E ratio: 0.49566948481161033
P/B ratio: 4.797606185013325
Pays dividend: no
Net asset value (USD): -54056645.99450163
Net cash (USD): -114302154.59369606
Net cash to market cap %: -30.846181488783387
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4483.T — Peter Lynch category analysis (quarterly, as of 2024-09-30)
Sector: Healthcare | Industry: Health Information Services
Lynch category:  (confidence: Medium)
Market cap (USD): 2114714338.1414769
P/B ratio: 4.1679515370683164
Pays dividend: no
Net asset value (USD): 56870710.18349909
Net cash (USD): -226586356.63258162
Net cash to market cap %: -10.714750098669011
Cyclical industry: no | Hot industry: no | Large cap: yes | Small cap: no
Piotroski F-score: 0 (Weak)
4483.T — Peter Lynch category analysis (quarterly, as of 2025-03-31)
Sector: Healthcare | Industry: Health Information Services
Lynch category:  (confidence: Low)
Market cap (USD): 1200635274.3633204
P/B ratio: 2.289124558779739
Pays dividend: no
Net asset value (USD): 92347279.7754311
Net cash (USD): -202553134.60767278
Net cash to market cap %: -16.870496722252625
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 3 (Weak)
4483.T — Peter Lynch category analysis (quarterly, as of 2025-06-30)
Sector: Healthcare | Industry: Health Information Services
Lynch category:  (confidence: Low)
Market cap (USD): 1794248319.9667864
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4483.T — Peter Lynch category analysis (quarterly, as of 2025-09-30)
Sector: Healthcare | Industry: Health Information Services
Lynch category:  (confidence: Low)
Market cap (USD): 1962232807.235532
P/B ratio: 3.649500552644622
Pays dividend: no
Net asset value (USD): 78209959.6231494
Net cash (USD): -237752355.3162853
Net cash to market cap %: -12.116419338194627
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4483.T — Peter Lynch category analysis (quarterly, as of 2026-03-31)
Sector: Healthcare | Industry: Health Information Services
Lynch category:  (confidence: High)
Market cap (USD): 1310169971.5715716
P/E ratio: 0.1979518581081081
P/B ratio: 2.518772351334014
Dividend yield: 0.01
Pays dividend: yes
Net asset value (USD): 94444444.44444445
Net cash (USD): -272309809.8098098
Net cash to market cap %: -20.784311632724222
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 2 (Weak)
4491.T — Peter Lynch category analysis (annual, as of 2022-03-31)
Sector: Technology | Industry: Software - Application
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 23982921.530896574
Net income (USD): 2894779.544336994
P/E ratio: 8.284887040125021
P/B ratio: 1.1319012885141493
Pays dividend: no
Net asset value (USD): 21011891.493197836
Net cash (USD): 7649164.071463693
Net cash to market cap %: 31.894212978220665
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 4.685198681842886 (Safe Zone)
Piotroski F-score: 3 (Weak)
4491.T — Peter Lynch category analysis (annual, as of 2023-03-31)
Sector: Technology | Industry: Software - Application
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 21545417.662912913
Net income (USD): 2534962.4624624625
EPS growth %: -12.429861285237955
Revenue growth %: -2.190314770853773
Smoothed growth %: -12.429861285237955
P/E ratio: 8.499304420462186
P/B ratio: 1.0063479097900339
Pays dividend: no
Net asset value (USD): 21283633.633633636
Net cash (USD): 8470765.765765768
Net cash to market cap %: 39.315857776787844
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 4.584640514924994 (Safe Zone)
Piotroski F-score: 6 (Neutral)
4491.T — Peter Lynch category analysis (annual, as of 2024-03-31)
Sector: Technology | Industry: Software - Application
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 20134092.587163232
Net income (USD): 2161958.53143159
EPS growth %: -14.714376901208087
Revenue growth %: -8.701675690048726
EPS 2-year CAGR %: -13.579667640444004
Smoothed growth %: -14.714376901208087
P/E ratio: 9.312894902674653
P/B ratio: 0.9535494724076107
Pays dividend: no
Net asset value (USD): 21026003.697834127
Net cash (USD): 8996249.33967248
Net cash to market cap %: 44.68167264418046
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 4.430465862332962 (Safe Zone)
Piotroski F-score: 6 (Neutral)
4491.T — Peter Lynch category analysis (annual, as of 2025-03-31)
Sector: Technology | Industry: Software - Application
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 23356988.70471862
Net income (USD): 2659316.9362384705
EPS growth %: 23.004992814434004
Revenue growth %: 11.183538432989645
EPS 2-year CAGR %: 2.423422401526043
Smoothed growth %: 2.423422401526043
P/E ratio: 8.783078235780511
P/B ratio: 0.9761156482783142
PEG ratio: 3.6242457073309864
Pays dividend: no
Net asset value (USD): 23863741.478411976
Net cash (USD): 11674883.037027135
Net cash to market cap %: 49.984538609074015
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 4.713553712996118 (Safe Zone)
Piotroski F-score: 8 (Strong)
4491.T — Peter Lynch category analysis (annual, as of 2026-03-31)
Sector: Technology | Industry: Software - Application
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 39328925.725725725
Net income (USD): 3202027.0270270268
EPS growth %: 20.407875548531067
Revenue growth %: -2.450007276417815
EPS 2-year CAGR %: 21.699506435516525
Smoothed growth %: 21.699506435516525
P/E ratio: 0.07239837798933052
P/B ratio: 1.4266576865903575
PEG ratio: 0.003336406669178104
Dividend yield: 0.02
Pays dividend: yes
Net asset value (USD): 25939520.77077077
Net cash (USD): 12298023.023023022
Net cash to market cap %: 31.269664238447977
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 5.675299990540953 (Safe Zone)
Piotroski F-score: 5 (Neutral)
4516.T — Peter Lynch category analysis (annual, as of 2022-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Medium)
Market cap (USD): 4153172110.387314
Net income (USD): 204868054.41730866
P/E ratio: 20.272424230316823
P/B ratio: 2.801630110509829
Pays dividend: no
Net asset value (USD): 1364809047.697099
Net cash (USD): 218660875.2663498
Net cash to market cap %: 5.264912444140391
Cyclical industry: no | Hot industry: no | Large cap: yes | Small cap: no
Altman Z-score: 10.598462849315396 (Safe Zone)
Piotroski F-score: 2 (Weak)
4516.T — Peter Lynch category analysis (annual, as of 2023-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Medium)
Market cap (USD): 2710185282.934234
Net income (USD): 171313813.81381384
EPS growth %: -16.378464030876223
Revenue growth %: -3.935130578776373
Smoothed growth %: -16.378464030876223
P/E ratio: 15.82000436858933
P/B ratio: 1.842468418406684
Pays dividend: no
Net asset value (USD): 1339857357.3573575
Net cash (USD): 225833333.33333337
Net cash to market cap %: 8.3327636215643
Cyclical industry: no | Hot industry: no | Large cap: yes | Small cap: no
Altman Z-score: 7.925375758590938 (Safe Zone)
Piotroski F-score: 5 (Neutral)
4516.T — Peter Lynch category analysis (annual, as of 2024-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Low)
Market cap (USD): 1868235008.0351954
Net income (USD): 170714474.37929213
EPS growth %: -0.34984886576226426
Revenue growth %: -9.555322828366341
EPS 2-year CAGR %: -8.715287712562292
Smoothed growth %: -0.34984886576226426
P/E ratio: 10.943623935978415
P/B ratio: 1.2829110686644687
Pays dividend: no
Net asset value (USD): 1288325409.403064
Net cash (USD): 170582408.87480187
Net cash to market cap %: 9.130671898403282
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Altman Z-score: 6.5718703868484205 (Safe Zone)
Piotroski F-score: 6 (Neutral)
4516.T — Peter Lynch category analysis (annual, as of 2025-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Low)
Market cap (USD): 1661769408.966181
Net income (USD): 217617965.51263198
EPS growth %: 27.47481799881247
Revenue growth %: 9.393333075495637
EPS 2-year CAGR %: 12.707075551586877
Smoothed growth %: 12.707075551586877
P/E ratio: 7.6361774867788705
P/B ratio: 1.0052354823522374
PEG ratio: 0.6009390166744742
Pays dividend: no
Net asset value (USD): 1328111215.078198
Net cash (USD): 148288998.79695228
Net cash to market cap %: 8.923560513080195
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Altman Z-score: 6.691435383979924 (Safe Zone)
Piotroski F-score: 9 (Strong)
4516.T — Peter Lynch category analysis (annual, as of 2026-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: High)
Market cap (USD): 1714540601.4014013
Net income (USD): 185985985.985986
EPS growth %: -14.535555211230875
Revenue growth %: -0.23710403760893342
EPS 2-year CAGR %: 4.377030733863574
Smoothed growth %: 4.377030733863574
P/E ratio: 0.07250938035687332
P/B ratio: 1.1807384476494591
PEG ratio: 0.01656588330438105
Dividend yield: 0.03
Pays dividend: yes
Net asset value (USD): 1522197197.1971972
Net cash (USD): 153378378.3783784
Net cash to market cap %: 8.945741982022044
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Altman Z-score: 5.334483576838388 (Safe Zone)
Piotroski F-score: 4 (Weak)
4523.T — Peter Lynch category analysis (annual, as of 2022-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Medium)
Market cap (USD): 11751398773.017868
Net income (USD): 393001147.352893
P/E ratio: 29.901690751212417
P/B ratio: 1.8585150321290733
Pays dividend: no
Net asset value (USD): 3783084740.2065234
Net cash (USD): -1292550401.5735126
Net cash to market cap %: -10.999119564739047
Cyclical industry: no | Hot industry: no | Large cap: yes | Small cap: no
Altman Z-score: 3.4816730557852216 (Safe Zone)
Piotroski F-score: 3 (Weak)
4523.T — Peter Lynch category analysis (annual, as of 2023-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Stalwart (confidence: Medium)
Market cap (USD): 14573506250.340092
Net income (USD): 426696696.69669676
EPS growth %: 8.573906099451422
Revenue growth %: -9.825711928482784
Smoothed growth %: 8.573906099451422
P/E ratio: 34.154251399558376
P/B ratio: 2.3599069655328235
PEG ratio: 3.9835112495276386
Pays dividend: no
Net asset value (USD): 3768108108.1081085
Net cash (USD): -1297965465.4654655
Net cash to market cap %: -8.906336218404379
Cyclical industry: no | Hot industry: no | Large cap: yes | Small cap: no
Altman Z-score: 4.222584861174372 (Safe Zone)
Piotroski F-score: 4 (Weak)
4523.T — Peter Lynch category analysis (annual, as of 2024-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Medium)
Market cap (USD): 10844635289.306063
Net income (USD): 289117802.4300053
EPS growth %: -32.242784003665456
Revenue growth %: -12.357605790859113
EPS 2-year CAGR %: -14.228993201978357
Smoothed growth %: -32.242784003665456
P/E ratio: 37.50939996831057
P/B ratio: 1.8268712346978613
Pays dividend: no
Net asset value (USD): 3656596671.949287
Net cash (USD): -1252647913.3650293
Net cash to market cap %: -11.550853301634499
Cyclical industry: no | Hot industry: no | Large cap: yes | Small cap: no
Altman Z-score: 3.5391680807170602 (Safe Zone)
Piotroski F-score: 6 (Neutral)
4523.T — Peter Lynch category analysis (annual, as of 2025-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Stalwart (confidence: Medium)
Market cap (USD): 7572194755.3762865
Net income (USD): 321207057.87996256
EPS growth %: 11.099024404671857
Revenue growth %: 7.71840946099809
EPS 2-year CAGR %: -13.237331797774953
Smoothed growth %: 11.099024404671857
P/E ratio: 23.57418546576916
P/B ratio: 1.308306749555873
Pays dividend: no
Net asset value (USD): 3560439780.777971
Net cash (USD): -1701176313.3270955
Net cash to market cap %: -22.46609296623352
Cyclical industry: no | Hot industry: no | Large cap: yes | Small cap: no
Altman Z-score: 2.82898187664142 (Grey Zone)
Piotroski F-score: 5 (Neutral)
4523.T — Peter Lynch category analysis (annual, as of 2026-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Medium)
Market cap (USD): 8221288655.055055
Net income (USD): 253503503.5035035
EPS growth %: -21.07785390001
Revenue growth %: -2.1276657643201777
EPS 2-year CAGR %: -6.3614746184463495
Smoothed growth %: -21.07785390001
P/E ratio: 0.2226183375281191
P/B ratio: 1.4860419534451095
Dividend yield: 0.03
Pays dividend: yes
Net asset value (USD): 3451370120.12012
Net cash (USD): -1737205955.9559557
Net cash to market cap %: -21.130579752698424
Cyclical industry: no | Hot industry: no | Large cap: yes | Small cap: no
Altman Z-score: 3.0173504753517078 (Safe Zone)
Piotroski F-score: 7 (Neutral)
4530.T — Peter Lynch category analysis (annual, as of 2022-02-28)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Low)
Net income (USD): 85326181.00017305
Pays dividend: no
Net asset value (USD): 2178932341.235508
Net cash (USD): 817226163.6961412
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 3 (Weak)
4530.T — Peter Lynch category analysis (annual, as of 2023-02-28)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Low)
Net income (USD): 88952464.7887324
EPS growth %: 4.249907526685148
Revenue growth %: -9.474249972921085
Smoothed growth %: 4.249907526685148
Pays dividend: no
Net asset value (USD): 1873657570.4225354
Net cash (USD): 596794307.5117371
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 7 (Neutral)
4530.T — Peter Lynch category analysis (annual, as of 2024-02-29)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Slow Grower (confidence: Low)
Net income (USD): 95785211.73503253
EPS growth %: 7.681346393861407
Revenue growth %: -0.08707824433244424
EPS 2-year CAGR %: 5.95173620054088
Smoothed growth %: 5.95173620054088
Pays dividend: no
Net asset value (USD): 1712737289.2605867
Net cash (USD): 422262046.99322975
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 7 (Neutral)
4530.T — Peter Lynch category analysis (annual, as of 2025-02-28)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Fast Grower (confidence: Medium)
Net income (USD): 148663422.4385041
EPS growth %: 55.204983885974826
Revenue growth %: 10.568346389429074
EPS 2-year CAGR %: 29.277537228550777
Smoothed growth %: 29.277537228550777
Pays dividend: no
Net asset value (USD): 1805539630.6912873
Net cash (USD): 436310912.60582626
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 7 (Neutral)
4534.T — Peter Lynch category analysis (quarterly, as of 2024-09-30)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 802243592.8922117
P/B ratio: 0.8872253392083125
Pays dividend: no
Net asset value (USD): 898998459.1679506
Net cash (USD): 163608348.50819445
Net cash to market cap %: 20.393849194651857
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 0 (Weak)
4534.T — Peter Lynch category analysis (quarterly, as of 2025-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 734248110.906296
P/B ratio: 0.8405821455915773
Pays dividend: no
Net asset value (USD): 867350621.5746558
Net cash (USD): 145181125.51797885
Net cash to market cap %: 19.77276119087036
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 2 (Weak)
4534.T — Peter Lynch category analysis (quarterly, as of 2025-06-30)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category:  (confidence: Low)
Market cap (USD): 708765124.186756
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4534.T — Peter Lynch category analysis (quarterly, as of 2025-09-30)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 747181960.6154778
P/B ratio: 0.8212066073552013
Pays dividend: no
Net asset value (USD): 902213997.30821
Net cash (USD): 149401076.71601617
Net cash to market cap %: 19.995273519846453
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4534.T — Peter Lynch category analysis (quarterly, as of 2026-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 690087950.3503504
P/E ratio: 0.09703535344560986
P/B ratio: 0.8717249367178814
Dividend yield: 0.03
Pays dividend: yes
Net asset value (USD): 870889639.6396396
Net cash (USD): -70939689.6896897
Net cash to market cap %: -10.279804139990324
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
4552.T — Peter Lynch category analysis (annual, as of 2022-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - General
Lynch category: Slow Grower (confidence: Medium)
Market cap (USD): 2051206709.6033442
Net income (USD): 118972299.62301263
P/E ratio: 17.241044479286355
P/B ratio: 4.899063256391788
Pays dividend: no
Net asset value (USD): 392730699.8852647
Net cash (USD): -123487952.79462382
Net cash to market cap %: -6.020258817235613
Cyclical industry: no | Hot industry: no | Large cap: yes | Small cap: no
Altman Z-score: 5.192404185192287 (Safe Zone)
Piotroski F-score: 2 (Weak)
4552.T — Peter Lynch category analysis (annual, as of 2023-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - General
Lynch category: Slow Grower (confidence: Low)
Market cap (USD): 1189755696.7267268
Net income (USD): 28430930.930930935
EPS growth %: -76.1028987243081
Revenue growth %: -38.411853672708766
Smoothed growth %: -76.1028987243081
P/E ratio: 41.84722968154211
P/B ratio: 3.0235906894091156
Pays dividend: no
Net asset value (USD): 364181681.6816817
Net cash (USD): -219564564.5645646
Net cash to market cap %: -18.45459241494988
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Altman Z-score: 3.428344368056519 (Safe Zone)
Piotroski F-score: 2 (Weak)
4552.T — Peter Lynch category analysis (annual, as of 2024-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - General
Lynch category: Fast Grower (confidence: Medium)
Market cap (USD): 646727873.1141045
Net income (USD): 36555731.64289488
EPS growth %: 28.577329147969294
Revenue growth %: 9.796629352076174
EPS 2-year CAGR %: -44.56873214144391
Smoothed growth %: 28.577329147969294
P/E ratio: 17.691558725505775
P/B ratio: 1.7342269872403717
Pays dividend: no
Net asset value (USD): 347860538.82725835
Net cash (USD): -178255414.68568408
Net cash to market cap %: -27.562661529857063
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Altman Z-score: 2.7796633568317923 (Grey Zone)
Piotroski F-score: 8 (Strong)
4552.T — Peter Lynch category analysis (annual, as of 2025-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - General
Lynch category: Turnaround (confidence: High)
Market cap (USD): 382083446.0072183
Net income (USD): -29381098.783585083
EPS growth %: -180.37343930249503
Revenue growth %: -21.918563267448675
Smoothed growth %: -180.37343930249503
P/B ratio: 1.1976227676624627
Pays dividend: no
Net asset value (USD): 296611415.5861516
Net cash (USD): -293536960.2994252
Net cash to market cap %: -76.82535408610184
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 1.2299958383824001 (Distress Zone)
Piotroski F-score: 1 (Weak)
4552.T — Peter Lynch category analysis (annual, as of 2026-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - General
Lynch category: Stalwart (confidence: Medium)
Market cap (USD): 394661541.5415415
Net income (USD): 13807557.557557557
Revenue growth %: 14.11782148319099
EPS 2-year CAGR %: -38.54167907865864
Smoothed growth %: 14.11782148319099
P/E ratio: 0.1991902216117463
P/B ratio: 1.4634084216305245
Dividend yield: 0.04
Pays dividend: yes
Net asset value (USD): 277414914.9149149
Net cash (USD): -299486986.986987
Net cash to market cap %: -75.8845125413527
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 1.4850242333753834 (Distress Zone)
Piotroski F-score: 5 (Neutral)
4554.T — Peter Lynch category analysis (quarterly, as of 2024-12-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category:  (confidence: Low)
Market cap (USD): 254268519.03477544
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 0 (Weak)
4554.T — Peter Lynch category analysis (quarterly, as of 2025-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 227365169.93984762
P/B ratio: 0.7438800097614311
Pays dividend: no
Net asset value (USD): 225511295.2813795
Net cash (USD): -268988103.19476
Net cash to market cap %: -118.30664444599157
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4554.T — Peter Lynch category analysis (quarterly, as of 2025-09-30)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 269269073.1569314
P/B ratio: 0.8530728977959707
Pays dividend: no
Net asset value (USD): 221810228.80215344
Net cash (USD): -264165545.0874832
Net cash to market cap %: -98.10467351128965
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 2 (Weak)
4554.T — Peter Lynch category analysis (quarterly, as of 2025-12-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category:  (confidence: Low)
Market cap (USD): 313217807.04063845
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4554.T — Peter Lynch category analysis (quarterly, as of 2026-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category:  (confidence: High)
Market cap (USD): 307050986.986987
P/E ratio: 0.14988683543924336
P/B ratio: 1.204275585046729
Dividend yield: 0.03
Pays dividend: yes
Net asset value (USD): 235410410.4104104
Net cash (USD): -223292042.04204205
Net cash to market cap %: -72.72148649745435
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4565.T — Peter Lynch category analysis (annual, as of 2021-12-31)
Sector: Healthcare | Industry: Biotechnology
Lynch category:  (confidence: Low)
Market cap (USD): 1519409458.1644192
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: yes | Large cap: no | Small cap: no
Piotroski F-score: 0 (Weak)
4565.T — Peter Lynch category analysis (annual, as of 2022-12-31)
Sector: Healthcare | Industry: Biotechnology
Lynch category: Slow Grower (confidence: Low)
Market cap (USD): 1475483051.8507376
Net income (USD): 2873909.1182666267
P/E ratio: 513.4063017068064
P/B ratio: 3.3851354469069324
Pays dividend: no
Net asset value (USD): 256191694.2521818
Net cash (USD): 188654829.97291607
Net cash to market cap %: 12.78597065118988
Cyclical industry: no | Hot industry: yes | Large cap: no | Small cap: no
Altman Z-score: 3.7767903279347186 (Safe Zone)
Piotroski F-score: 4 (Weak)
4565.T — Peter Lynch category analysis (annual, as of 2023-12-31)
Sector: Healthcare | Industry: Biotechnology
Lynch category: Turnaround (confidence: High)
Market cap (USD): 921657143.7035989
Net income (USD): -50859082.23149261
EPS growth %: -1869.6830393219886
Revenue growth %: -22.93753216250227
Smoothed growth %: -22.93753216250227
P/B ratio: 1.951054779733573
Pays dividend: no
Net asset value (USD): -71441702.60906455
Net cash (USD): -289945556.1054939
Net cash to market cap %: -31.459155726865305
Cyclical industry: no | Hot industry: yes | Large cap: no | Small cap: no
Altman Z-score: 0.9689413282666717 (Distress Zone)
Piotroski F-score: 2 (Weak)
4565.T — Peter Lynch category analysis (annual, as of 2024-12-31)
Sector: Healthcare | Industry: Biotechnology
Lynch category: Turnaround (confidence: High)
Market cap (USD): 608945647.6341294
Net income (USD): -30817249.50633798
Revenue growth %: 103.48606221676737
Smoothed growth %: 103.48606221676737
P/B ratio: 1.3952301179556026
Pays dividend: no
Net asset value (USD): -57876297.85336645
Net cash (USD): -297961653.60851014
Net cash to market cap %: -48.930746900999836
Cyclical industry: no | Hot industry: yes | Large cap: no | Small cap: no
Altman Z-score: 0.9043634357470035 (Distress Zone)
Piotroski F-score: 4 (Weak)
4565.T — Peter Lynch category analysis (annual, as of 2025-12-31)
Sector: Healthcare | Industry: Biotechnology
Lynch category: Turnaround (confidence: High)
Market cap (USD): 486261549.6314339
Net income (USD): -80109967.39338917
Revenue growth %: 3.0858970901052536
Smoothed growth %: 3.0858970901052536
P/B ratio: 1.2468837644122264
Pays dividend: no
Net asset value (USD): -89962278.62668628
Net cash (USD): -341570232.0823477
Net cash to market cap %: -70.24413761302817
Cyclical industry: no | Hot industry: yes | Large cap: no | Small cap: yes
Altman Z-score: 0.6887895036879754 (Distress Zone)
Piotroski F-score: 4 (Weak)
4572.T — Peter Lynch category analysis (quarterly, as of 2025-03-31)
Sector: Healthcare | Industry: Biotechnology
Lynch category:  (confidence: Low)
Market cap (USD): 37186295.6823954
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: yes | Large cap: no | Small cap: yes
Piotroski F-score: 0 (Weak)
4572.T — Peter Lynch category analysis (quarterly, as of 2025-06-30)
Sector: Healthcare | Industry: Biotechnology
Lynch category:  (confidence: Low)
Market cap (USD): 46065532.16163852
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: yes | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4572.T — Peter Lynch category analysis (quarterly, as of 2025-12-31)
Sector: Healthcare | Industry: Biotechnology
Lynch category:  (confidence: Low)
Market cap (USD): 43779634.536247686
P/B ratio: 22.144806052087848
Pays dividend: no
Net asset value (USD): 1976970.7819193148
Net cash (USD): -2580659.8043603348
Net cash to market cap %: -5.894658170852609
Cyclical industry: no | Hot industry: yes | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4572.T — Peter Lynch category analysis (quarterly, as of 2026-03-31)
Sector: Healthcare | Industry: Biotechnology
Lynch category:  (confidence: Low)
Market cap (USD): 36249001.001001
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: yes | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
457A.T — Peter Lynch category analysis (quarterly, as of 2025-02-28)
Sector: Consumer Cyclical | Industry: Personal Services
Lynch category:  (confidence: Low)
Pays dividend: no
Net cash (USD): 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 0 (Weak)
457A.T — Peter Lynch category analysis (quarterly, as of 2025-08-31)
Sector: Consumer Cyclical | Industry: Personal Services
Lynch category:  (confidence: Low)
Pays dividend: no
Net cash (USD): 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
457A.T — Peter Lynch category analysis (quarterly, as of 2026-02-28)
Sector: Consumer Cyclical | Industry: Personal Services
Lynch category:  (confidence: Low)
Market cap (USD): 5681201.077890414
P/E ratio: 0.1238635972319551
P/B ratio: 3.0159436234021464
Pays dividend: no
Net asset value (USD): 1727049.916591813
Net cash (USD): 231861.92737071728
Net cash to market cap %: 4.081213183477287
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4586.T — Peter Lynch category analysis (quarterly, as of 2025-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category:  (confidence: Low)
Market cap (USD): 30551480.72450207
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 0 (Weak)
4586.T — Peter Lynch category analysis (quarterly, as of 2025-06-30)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 30397296.23581511
P/B ratio: 2.3466546291360095
Pays dividend: no
Net asset value (USD): 12953459.728757264
Net cash (USD): 11107154.719070023
Net cash to market cap %: 36.53994300316487
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4586.T — Peter Lynch category analysis (quarterly, as of 2025-12-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category: Asset Play (confidence: Medium)
Market cap (USD): 41096279.623101085
P/B ratio: 3.137091491832191
Pays dividend: no
Net asset value (USD): 13100121.475608977
Net cash (USD): 10524429.384310465
Net cash to market cap %: 25.609202294785007
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4586.T — Peter Lynch category analysis (quarterly, as of 2026-03-31)
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic
Lynch category:  (confidence: Low)
Market cap (USD): 23398404.804804806
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
458A.T — Peter Lynch category analysis (annual, as of 2023-11-30)
Sector: Real Estate | Industry: Real Estate Services
Lynch category:  (confidence: Low)
Pays dividend: no
Net cash (USD): 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 0 (Weak)
458A.T — Peter Lynch category analysis (annual, as of 2024-11-30)
Sector: Real Estate | Industry: Real Estate Services
Lynch category:  (confidence: Low)
Pays dividend: no
Net cash (USD): 0
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: no
Piotroski F-score: 1 (Weak)
458A.T — Peter Lynch category analysis (annual, as of 2025-11-30)
Sector: Real Estate | Industry: Real Estate Services
Lynch category: Slow Grower (confidence: High)
Market cap (USD): 25014458.152034808
Net income (USD): 3119484.2590222675
P/E ratio: 0.0776541778070832
P/B ratio: 2.211124629241243
Dividend yield: 0.01
Pays dividend: yes
Net asset value (USD): 11311127.463527003
Net cash (USD): -36652450.72945994
Net cash to market cap %: -146.52506365195217
Cyclical industry: no | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 2.207813618733063 (Grey Zone)
Piotroski F-score: 4 (Weak)
4616.T — Peter Lynch category analysis (quarterly, as of 2025-05-31)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 11157415.377312561
P/B ratio: 0.5081150401227675
Pays dividend: no
Net asset value (USD): 21879357.351509254
Net cash (USD): -21909549.311448045
Net cash to market cap %: -196.36760459773527
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 0 (Weak)
4616.T — Peter Lynch category analysis (quarterly, as of 2025-11-30)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 13879273.515485026
P/B ratio: 0.6504368871191145
Pays dividend: no
Net asset value (USD): 21283401.586895317
Net cash (USD): -22077585.1036601
Net cash to market cap %: -159.0687371282673
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4616.T — Peter Lynch category analysis (quarterly, as of 2026-02-28)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 12869251.411523161
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4616.T — Peter Lynch category analysis (quarterly, as of 2026-05-31)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 12456218.697808752
P/E ratio: 0.047451834892418575
P/B ratio: 0.5117881373755516
Dividend yield: 0.02
Pays dividend: yes
Net asset value (USD): 22035756.890814338
Net cash (USD): -17868424.687637344
Net cash to market cap %: -143.4498311335902
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4619.T — Peter Lynch category analysis (quarterly, as of 2024-09-30)
Sector: Consumer Cyclical | Industry: Auto Parts
Lynch category: Cyclical (confidence: High)
Market cap (USD): 157895660.45881775
P/B ratio: 0.3634835851266465
Pays dividend: no
Net asset value (USD): 380172293.0382407
Net cash (USD): -65912592.80011207
Net cash to market cap %: -41.744397919855025
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 0 (Weak)
4619.T — Peter Lynch category analysis (quarterly, as of 2025-03-31)
Sector: Consumer Cyclical | Industry: Auto Parts
Lynch category: Cyclical (confidence: High)
Market cap (USD): 197825457.47974867
P/B ratio: 0.4616637023399309
Pays dividend: no
Net asset value (USD): 375384306.9108408
Net cash (USD): -32716214.409838244
Net cash to market cap %: -16.5379192479246
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 3 (Weak)
4619.T — Peter Lynch category analysis (quarterly, as of 2025-06-30)
Sector: Consumer Cyclical | Industry: Auto Parts
Lynch category: Cyclical (confidence: High)
Market cap (USD): 276926140.2167866
Pays dividend: no
Net cash (USD): 0
Net cash to market cap %: 0
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4619.T — Peter Lynch category analysis (quarterly, as of 2025-09-30)
Sector: Consumer Cyclical | Industry: Auto Parts
Lynch category: Cyclical (confidence: High)
Market cap (USD): 292165279.25
P/B ratio: 0.6828632173602918
Pays dividend: no
Net asset value (USD): 380323014.8048452
Net cash (USD): -25074024.226110354
Net cash to market cap %: -8.582136895416314
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)
4619.T — Peter Lynch category analysis (quarterly, as of 2026-03-31)
Sector: Consumer Cyclical | Industry: Auto Parts
Lynch category: Cyclical (confidence: High)
Market cap (USD): 324497502.3023023
P/E ratio: 0.0561147829899377
P/B ratio: 0.6906558484378263
Dividend yield: 0.06
Pays dividend: yes
Net asset value (USD): 369219219.2192192
Net cash (USD): -15872122.122122124
Net cash to market cap %: -4.89129253985309
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 3 (Weak)
4623.T — Peter Lynch category analysis (annual, as of 2022-03-31)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 50836585.43435502
Net income (USD): 8226987.379118178
P/E ratio: 6.179246799793197
P/B ratio: 0.46811767092318957
Pays dividend: no
Net asset value (USD): 106630765.44828717
Net cash (USD): -15475446.648090474
Net cash to market cap %: -30.441554081309857
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 2.1390035800919236 (Grey Zone)
Piotroski F-score: 3 (Weak)
4623.T — Peter Lynch category analysis (annual, as of 2023-03-31)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 46502033.33175676
Net income (USD): 4907349.84984985
EPS growth %: -40.35058492607227
Revenue growth %: 10.347465604484949
Smoothed growth %: -40.35058492607227
P/E ratio: 9.475997178635957
P/B ratio: 0.4578040085988417
Pays dividend: no
Net asset value (USD): 93274827.32732734
Net cash (USD): -29129361.861861862
Net cash to market cap %: -62.641049809684546
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 1.9980312972639953 (Grey Zone)
Piotroski F-score: 4 (Weak)
4623.T — Peter Lynch category analysis (annual, as of 2024-03-31)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 41949958.56358954
Net income (USD): 2512447.173798204
EPS growth %: -48.80236276867285
Revenue growth %: -12.169934253370258
EPS 2-year CAGR %: -44.737814791524855
Smoothed growth %: -48.80236276867285
P/E ratio: 16.696851978054326
P/B ratio: 0.463560956608914
Pays dividend: no
Net asset value (USD): 84169974.90755415
Net cash (USD): -26166600.63391442
Net cash to market cap %: -62.37574846289768
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 2.035706760533042 (Grey Zone)
Piotroski F-score: 6 (Neutral)
4623.T — Peter Lynch category analysis (annual, as of 2025-03-31)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 42269192.71888784
Net income (USD): 4689346.344071648
EPS growth %: 86.64457477856166
Revenue growth %: 1.4844610850987812
EPS 2-year CAGR %: -2.2464259952194143
Smoothed growth %: 86.64457477856166
P/E ratio: 9.01387733331433
P/B ratio: 0.4469101753822625
Pays dividend: no
Net asset value (USD): 89182134.74134474
Net cash (USD): -27051430.29006817
Net cash to market cap %: -63.99798186346798
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 2.100226320326918 (Grey Zone)
Piotroski F-score: 7 (Neutral)
4623.T — Peter Lynch category analysis (annual, as of 2026-03-31)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 39872723.923923925
Net income (USD): 4552927.927927928
EPS growth %: -2.9091136831081483
Revenue growth %: -8.18918958321753
EPS 2-year CAGR %: 34.616073302893334
Smoothed growth %: 34.616073302893334
P/E ratio: 0.05481514319576568
P/B ratio: 0.4253408292105764
PEG ratio: 0.0015835170764785743
Dividend yield: 0.03
Pays dividend: yes
Net asset value (USD): 89707057.05705705
Net cash (USD): -41846365.11511511
Net cash to market cap %: -104.9498529244123
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Altman Z-score: 1.6144503770681462 (Distress Zone)
Piotroski F-score: 5 (Neutral)
4627.T — Peter Lynch category analysis (quarterly, as of 2025-04-30)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 72179755.43464512
P/B ratio: 0.4389635000097656
Pays dividend: no
Net asset value (USD): 162130702.74068868
Net cash (USD): -41290358.39775123
Net cash to market cap %: -57.20490205198523
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 0 (Weak)
4627.T — Peter Lynch category analysis (quarterly, as of 2025-10-31)
Sector: Basic Materials | Industry: Specialty Chemicals
Lynch category: Cyclical (confidence: High)
Market cap (USD): 76173516.7748538
P/B ratio: 0.47684079457939793
Pays dividend: no
Net asset value (USD): 156459662.1182586
Net cash (USD): 34235828.46003898
Net cash to market cap %: 44.9445291612699
Cyclical industry: yes | Hot industry: no | Large cap: no | Small cap: yes
Piotroski F-score: 1 (Weak)